| Assessment Status | Rapid Review complete |
| HTA ID | 21031 |
| Drug | Blinatumomab |
| Brand | Blincyto® |
| Indication | Treatment of paediatric patients (aged 1 year plus) with high-risk first-relapsed Ph- CD19+ B-precursor acute lymphoblastic leukaemia as part of consolidation therapy. |
| Assessment Process | |
| Rapid review commissioned | 05/07/2021 |
| Rapid review completed | 03/08/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that blinatumomab not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement following confidential price negotiations May 2022.
